Soleno Therapeutics Inc
SLNODelisted May 18, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001484565
Soleno Therapeutics Inc was delisted on May 18, 2026; its insiders filed their last Form 4 on May 18, 2026; 230 institutions reported holding it in 13F filings for Q1 2026, worth $2.09B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 230
- Q1 2026, −14 vs. previous quarter
- 13F value
- $2.09B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 0
- At the end of Q1 2026
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $190.4M
- No comparable prior period
- Net income, FY2025
- $20.9M
- No comparable prior period
- Free cash flow, FY2025
- $46.7M
- No comparable prior period
- Revenue, Q1 FY2026
- $94.6M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date May 15, 2026.
- Short interest
- 4.41M
- Shares sold short
- Change
- −2.12M
- −32.5% vs. previous
- Days to cover
- 2.31
- At average daily volume
Superinvestors holding SLNO, Q1 2026
Go to the superinvestors tabNo superinvestor reported holding SLNO at the end of Q1 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Soleno Therapeutics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 (view filing) | Mar 27 | 4 days | Huang Michael F.Sr. VP of Clinical Development | SSale | −6.58K | $30.44 | −$200.4K | −14.2%39.8K after | 3 lots |
| Mar 31, 2026 (view filing) | Mar 27 | 4 days | Manning MeredithChief Commercial Officer | SSale | −7.52K | $30.44 | −$229.0K | −10.4%64.5K after | 3 lots |
| Jul 3, 2025 (view filing) | Jul 1 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −3.83K | $82.76 | −$317.0K | −22.5%13.2K after | 10b5-1 |
| Jun 26, 2025 (view filing) | Jun 24 | 2 days | Hirano Patricia CSEE REMARKS | SSale | −266 | $84.25 | −$22.4K | −1.5%17.0K after | 10b5-1 |
| Apr 2, 2025 (view filing) | Apr 1 | 1 day | Hirano Patricia CSEE REMARKS | SSale | −3.78K | $70.11 | −$265.2K | −12.3%27.0K after | 10b5-1 |
| Mar 31, 2025 (view filing) | Mar 28 | 3 days | Pauls MatthewDirector | SSale | −5.94K | $71.55 | −$424.8K | −47.7%6.50K after | |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Yen KristenSEE REMARKS | SSale | −95.5K | $66.77 | −$6.38M | −77.2%28.1K after | 10 lots |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Manning MeredithChief Commercial Officer | SSale | −45.2K | $67.28 | −$3.04M | −49.9%45.4K after | 9 lots |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Mackaness James HCHIEF FINANCIAL OFFICER | SSale | −90.6K | $69.45 | −$6.29M | −46.3%105.2K after | 11 lots |
| Mar 31, 2025 (view filing) | Mar 27 | 4 days | Huang Michael F.Sr. VP of Clinical Development | SSale | −14.6K | $69.51 | −$1.01M | −28.4%36.8K after | 9 lots |
Top 10 13F holders, Q1 2026
See all 230 holdersThe largest institutional positions in Soleno Therapeutics Inc at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Janus Henderson Group PLC | 7,099,328 | $237.6M | 0.11% | −79,026−1.1% | Reduced |
| FMR LLC | 5,788,410 | $193.8M | 0.01% | −2,290,894−28.4% | Reduced |
| Wellington Management Group LLP | 4,426,781 | $148.2M | 0.03% | +1,103,982+33.2% | Added |
| BlackRock, Inc. | 3,742,774 | $125.3M | 0.00% | −128,865−3.3% | Reduced |
| State Street Corp | 2,680,802 | $89.8M | 0.00% | +31,176+1.2% | Added |
| Avoro Capital Advisors LLC | 2,300,000 | $77.0M | 0.76% | −600,000−20.7% | Reduced |
| Vanguard Capital Management LLC | 2,153,218 | $72.1M | 0.00% | +2,153,218 | New |
| Nantahala Capital Management, LLC | 1,744,124 | $58.4M | 3.64% | +430,122+32.7% | Added |
| Polar Capital Holdings Plc | 1,698,855 | $56.9M | 0.25% | +561,926+49.4% | Added |
| Khrom Capital Management LLC | 1,511,481 | $50.6M | 4.63% | +1,511,481 | New |
Holders of 5% or more of SLNO
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Soleno Therapeutics Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 6.90%3.54M shares | +1.40 ppfrom 5.50% | Oct 24, 20244 filings | Apr 24, 2026 | SEC |
| Adage Capital Partners GP, L.L.C. | 13G/A | 6.44%2.78M shares | – | Oct 12, 20233 filings | Feb 12, 2025 | SEC |
| State Street Corp | 13G | 5.20%2.68M shares | New | May 12, 20261 filing | May 12, 2026 | SEC |